Shots:
- IMPACT Therapeutics has entered into an exclusive licensing agreement with Pharmanovia for the exclusive rights to manufacture, develop, and commercialise senaparib in EMEA, Australia, and New Zealand
- As per the deal, Pharmanovia will acquire exclusive rights to manufacture, develop & commercialise senaparib across EMEA, Australia & New Zealand, with IMPACT eligible for upfront, regulatory & sales-based milestones of up to ~$496.77(€423.5M), plus tiered royalties up to the mid-twenties (%) on net sales. The partnership expands senaparib’s reach to 66 countries
- Senaparib is a PARP1/2 inhibitor developed by IMPACT, offering high target selectivity and a favorable safety profile
Ref: PRNewsWire | Image: IMPACT Therapeutics & Pharmanovia | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
